[Immune-checkpoint and hemopathies].
Immune-checkpoint inhibitors represent potent new therapies for most lymphomas, particularly for refractory diseases. Contrasting with solid tumors the majority of lymphoma are sensitive to conventional therapies and immunotherapies such as anti-CD20 or anti-CD30. But relapsing lymphoma or refractory disease have a very poor prognosis and new drugs are mandatory. Immune-checkpoint inhibitors targeting CTLA4, PD-1 et PD-L1 demonstrated efficiency with prolonged survivals even after bone marrow allograft for aggressive disease. Lymphomas differ from solid tumors as tumor cells belong to the immune compartment and therefore molecules targeting immune cells may act on both immune environment and tumor cells. Furthermore, PD-L1 expression in most lymphomas is related to tumor cell molecular alterations such as PD-L1 gene amplification or mutation. PD-L1 protein expression on tumor cells and immune cells, particularly it frequency and distribution vary according to different lymphoma subtype and it may help to assess diagnosis as it may predict therapeutical response.
Service de pathologie, hôpital Cochin, AP-HP , 75014 Paris, France.
Barbara
B
Burroni
Service de pathologie, hôpital Cochin, AP-HP , 75014 Paris, France.
Chloé
C
Broudin
Service de pathologie, hôpital Cochin, AP-HP , 75014 Paris, France; Inserm U1138, centre de recherche des Cordeliers, 15, rue de l'École de Médecine, 75006 Paris, France; Université Paris Descartes, 75006 Paris, France; Université Pierre-et-Marie-Curie, 75005 Paris, France. Electronic address: diane.damotte@aphp.fr.
Diane
D
Damotte
Département de pathologie, institut universitaire du cancer-oncopole de Toulouse, 31059 Toulouse, France; Service de pathologie et cytologie, centre hospitalier universitaire, 31300 Toulouse, France; Inserm UMR1037, centre de recherches en cancérologie de Toulouse, 31100 Toulouse, France.
Camille
C
Laurent
D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D002869:Chromosome Aberrations; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D019337:Hematologic Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D008223:Lymphoma / Q000188:drug therapy / Q000235:genetics / Q000276:immunology / Q000628:therapy; D018448:Models, Immunological; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D011379:Prognosis; D061026:Programmed Cell Death 1 Receptor / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology
D000074322:Antineoplastic Agents, Immunological; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D009363:Neoplasm Proteins; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor
Cellules immunitaires; Hemopathies; Hémopathies; Immune cells; PD-1; PD-L1